Showing 5 posts of 5 posts found.


FDA advisory committee votes down approval of Boehringer and Lilly’s drug for type 1 diabetes

November 14, 2019
Sales and Marketing Boehringer Ingelheim, Eli Lilly, empagliflozin, jardiance, pharma

Boehringer Ingelheim and Eli Lilly’s have been dealt a blow from the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), …

Jardiance scores more cardiovascular outcomes data

November 10, 2015
Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes

A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …


More positive CV data for Boehringer and Lilly’s Jardiance

September 21, 2015
Research and Development, Sales and Marketing Boehringer Ingelheim, EASD, Eli Lilly, cardiovascular risk, empagliflozin, jardiance, mortality risk, type 2 diabetes

Jardiance, an anti-diabetes drug produced by Boehringer Ingelheim and Eli Lilly, reduces the risk of death in people with type …

Boehringer assures future growth following sales drop

April 23, 2015
Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results

Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …

Glyxambi image

Boehringer and Lilly score FDA yes for Glyxambi

February 3, 2015
Sales and Marketing Boehringer, FDA, Glyxambi, Tradjenta, empagliflozin, jardiance, lilly, linagliptin

The FDA has approved Glyxambi (empagliflozin/linagliptin), which has become the first combination of two diabetes drugs in their different classes …

Latest content